WO1999012964A3 - Kay - a novel immune system protein - Google Patents

Kay - a novel immune system protein Download PDF

Info

Publication number
WO1999012964A3
WO1999012964A3 PCT/US1998/019037 US9819037W WO9912964A3 WO 1999012964 A3 WO1999012964 A3 WO 1999012964A3 US 9819037 W US9819037 W US 9819037W WO 9912964 A3 WO9912964 A3 WO 9912964A3
Authority
WO
WIPO (PCT)
Prior art keywords
kay
immune system
system protein
novel immune
novel
Prior art date
Application number
PCT/US1998/019037
Other languages
French (fr)
Other versions
WO1999012964A2 (en
Inventor
Jurg Tschopp
Original Assignee
Biogen Inc
Jurg Tschopp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU93152/98A priority Critical patent/AU9315298A/en
Priority to HU0004034A priority patent/HUP0004034A3/en
Priority to EEP200000148A priority patent/EE200000148A/en
Priority to KR1020007002576A priority patent/KR20010023892A/en
Application filed by Biogen Inc, Jurg Tschopp filed Critical Biogen Inc
Priority to JP2000510769A priority patent/JP2001515711A/en
Priority to CA002303424A priority patent/CA2303424A1/en
Priority to BR9812433-1A priority patent/BR9812433A/en
Priority to EP98946052A priority patent/EP1012270A2/en
Priority to IL13448098A priority patent/IL134480A0/en
Priority to EA200000311A priority patent/EA200000311A1/en
Priority to SK353-2000A priority patent/SK3532000A3/en
Publication of WO1999012964A2 publication Critical patent/WO1999012964A2/en
Publication of WO1999012964A3 publication Critical patent/WO1999012964A3/en
Priority to IS5375A priority patent/IS5375A/en
Priority to NO20001240A priority patent/NO20001240L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Kay-ligand, a novel member of the tumor necrosis factor family (TNF), modified Kay-ligands and pharmaceutical compositions comprising them.
PCT/US1998/019037 1997-09-12 1998-09-11 Kay - a novel immune system protein WO1999012964A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CA002303424A CA2303424A1 (en) 1997-09-12 1998-09-11 Kay - a novel immune system protein
EEP200000148A EE200000148A (en) 1997-09-12 1998-09-11 Kay - a new protein in the immune system
KR1020007002576A KR20010023892A (en) 1997-09-12 1998-09-11 Kay-a novel immune system protein
EP98946052A EP1012270A2 (en) 1997-09-12 1998-09-11 Kay - a novel immune system protein
JP2000510769A JP2001515711A (en) 1997-09-12 1998-09-11 Kay-a novel immune system protein
HU0004034A HUP0004034A3 (en) 1997-09-12 1998-09-11 Kay - a novel immune system protein
BR9812433-1A BR9812433A (en) 1997-09-12 1998-09-11 Kay- a protein of the immunization system
AU93152/98A AU9315298A (en) 1997-09-12 1998-09-11 Kay - a novel immune system protein
IL13448098A IL134480A0 (en) 1997-09-12 1998-09-11 Kay - an immune system protein and dna sequences encoding the same
EA200000311A EA200000311A1 (en) 1997-09-12 1998-09-11 NEW PROTEIN IMMUNE SYSTEM - KAU
SK353-2000A SK3532000A3 (en) 1997-09-12 1998-09-11 Dna sequence coding for kay ligand, method for the preparation of kay ligand, pharmaceutical composition containing said ligand and the use thereof
IS5375A IS5375A (en) 1997-09-12 2000-02-11 KAY-Innovative Immune Protein
NO20001240A NO20001240L (en) 1997-09-12 2000-03-09 Kay-A immune system protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
US60/058,786 1997-09-12

Publications (2)

Publication Number Publication Date
WO1999012964A2 WO1999012964A2 (en) 1999-03-18
WO1999012964A3 true WO1999012964A3 (en) 1999-05-27

Family

ID=22018915

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/019037 WO1999012964A2 (en) 1997-09-12 1998-09-11 Kay - a novel immune system protein

Country Status (17)

Country Link
EP (1) EP1012270A2 (en)
JP (1) JP2001515711A (en)
KR (1) KR20010023892A (en)
CN (1) CN1269832A (en)
AU (1) AU9315298A (en)
BR (1) BR9812433A (en)
CA (1) CA2303424A1 (en)
EA (1) EA200000311A1 (en)
EE (1) EE200000148A (en)
HU (1) HUP0004034A3 (en)
IL (1) IL134480A0 (en)
IS (1) IS5375A (en)
NO (1) NO20001240L (en)
PL (1) PL339740A1 (en)
SK (1) SK3532000A3 (en)
TR (1) TR200000654T2 (en)
WO (1) WO1999012964A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
JP2002503444A (en) * 1997-11-26 2002-02-05 イーライ・リリー・アンド・カンパニー Ligand family genes
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
WO1999033980A2 (en) * 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
DK1415659T3 (en) 1999-01-25 2011-10-03 Biogen Idec Inc BAFF, inhibitors and its use in modulating B cell response
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
NZ513290A (en) * 1999-02-23 2004-05-28 Human Genome Sciences Inc Neutrokine-alpha and neutrokine-alpha splice variant
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
US6475987B1 (en) 1999-05-06 2002-11-05 National Jewish Medical And Research Center Tall-1 receptor homologues
ATE360693T1 (en) * 1999-08-17 2007-05-15 Biogen Idec Inc BAFF RECEPTOR (BCMA), AN IMMUNOREGULATORY AGENT
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
CA2897626C (en) 2000-02-11 2020-03-24 Biogen Idec Ma Inc. Heterologous polypeptide of the tnf family
DK1255558T3 (en) 2000-02-16 2006-10-23 Genentech Inc Anti-April antibodies and hybridoma cells
US6774106B2 (en) 2000-05-12 2004-08-10 Amgen Inc. Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3 and TACI
ATE494304T1 (en) 2000-06-16 2011-01-15 Human Genome Sciences Inc IMMUNE-SPECIFIC BINDING ANTIBODIES AGAINST BLYS
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
CA2419661A1 (en) * 2000-08-15 2002-03-07 Guo-Liang Yu Neutrokine-alpha and neutrokine-alpha splice variant
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
UA83458C2 (en) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
CN1970077A (en) 2001-05-11 2007-05-30 安姆根有限公司 Peptides and related molecules that bind to tall-1
AR035119A1 (en) 2001-08-16 2004-04-14 Lilly Co Eli ANTI-HTNFSF13B HUMAN ANTI-BODIES
WO2004094620A2 (en) 2003-03-28 2004-11-04 Biogen Idec Ma Inc. Truncated baff receptors
WO2005005462A2 (en) 2003-06-05 2005-01-20 Genentech, Inc. Blys antagonists and uses thereof
KR20070001880A (en) 2003-10-20 2007-01-04 바이오겐 아이덱 엠에이 인코포레이티드 Therapeutic regimens for baff antagonists
WO2005075511A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
CN101087807A (en) 2004-10-05 2007-12-12 健泰科生物技术公司 Method for treating vasculitis
WO2006044582A2 (en) 2004-10-13 2006-04-27 The Washington University Use of baff to treat sepsis
JP2008525002A (en) 2004-12-23 2008-07-17 ラボラトワール セローノ ソシエテ アノニム BCMA polypeptides and uses thereof
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
EA016083B1 (en) 2005-08-09 2012-02-28 Займоджинетикс, Инк. Methods for treating b-non-hodgkin's lymphoma using taci-ig fusion molecule
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
ES2618543T3 (en) 2005-11-23 2017-06-21 Genentech, Inc. Methods and compositions related to B lymphocyte assays
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
CN101489573B (en) 2006-05-15 2013-05-22 阿雷斯贸易股份有限公司 Methods for treating autoimmune diseases using a TACI-Ig fusion molecule
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
KR20120104517A (en) 2009-09-03 2012-09-21 제넨테크, 인크. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
RU2013140975A (en) 2011-02-28 2015-04-10 Дженентек, Инк. BIOLOGICAL MARKERS AND METHODS FOR PREDICTING SUSCEPTIBILITY TO B-CELL ANTAGONISTS
JP6636803B2 (en) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Method for selection of antibodies to BCMA
JOP20140087B1 (en) 2013-03-13 2021-08-17 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
US10138251B2 (en) 2014-04-11 2018-11-27 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018325A1 (en) * 1993-02-03 1994-08-18 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them
WO1996040774A1 (en) * 1995-06-07 1996-12-19 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical preparations
WO1998018921A1 (en) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. NEUTROKINE $g(a)
WO1998027114A2 (en) * 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
EP0869180A1 (en) * 1997-04-02 1998-10-07 Smithkline Beecham Corporation A TNF homologue, TL5

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018325A1 (en) * 1993-02-03 1994-08-18 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them
WO1996040774A1 (en) * 1995-06-07 1996-12-19 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical preparations
WO1998018921A1 (en) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. NEUTROKINE $g(a)
WO1998027114A2 (en) * 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
EP0869180A1 (en) * 1997-04-02 1998-10-07 Smithkline Beecham Corporation A TNF homologue, TL5

Also Published As

Publication number Publication date
TR200000654T2 (en) 2000-07-21
JP2001515711A (en) 2001-09-25
CA2303424A1 (en) 1999-03-18
HUP0004034A2 (en) 2001-03-28
NO20001240D0 (en) 2000-03-09
AU9315298A (en) 1999-03-29
EE200000148A (en) 2001-02-15
IL134480A0 (en) 2001-04-30
PL339740A1 (en) 2001-01-02
HUP0004034A3 (en) 2002-08-28
CN1269832A (en) 2000-10-11
IS5375A (en) 2000-02-11
NO20001240L (en) 2000-05-10
EP1012270A2 (en) 2000-06-28
WO1999012964A2 (en) 1999-03-18
BR9812433A (en) 2000-09-26
SK3532000A3 (en) 2001-12-03
EA200000311A1 (en) 2000-10-30
KR20010023892A (en) 2001-03-26

Similar Documents

Publication Publication Date Title
WO1999012964A3 (en) Kay - a novel immune system protein
WO1999012965A3 (en) April- a novel protein with growth effects
EP1591530B8 (en) A tumor necrosis factor related ligand
AU1102399A (en) Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
ZA947122B (en) Drug binding protein.
AU2526797A (en) Stimulation of immune response with low doses of interleukin-2
AU9597398A (en) Increasing the digestibility of food proteins by thioredoxin reduction
AU7705198A (en) Human tumor necrosis factor receptor tr10
AU7705098A (en) Human tumor necrosis factor receptor-like protein 8
AU7624598A (en) 1,4-diazabicyclo (2.2.2) Oct-2-ylmethyl derivatives, their preparation and the rapeutic application
AU3003095A (en) Proteins associated with tumor necrosis factor receptor
AU1541699A (en) Human tumor necrosis factor-r2-like proteins
AU7495796A (en) Novel oligopeptides, the preparation and use thereof
AU1750997A (en) Obesity protein formulations
AU1705197A (en) Obesity protein formulations
AU1568999A (en) Pharmaceutical compositions based on dalforpristin and quinupristin and preparation
AU2243997A (en) Obesity protein formulations
AU5358894A (en) Recombinant alliinase, its preparation and pharmaceutical compositions comprising it
AU5777696A (en) Candida heat shock protein, cdna and uses thereof
AU1747297A (en) Obesity protein formulations
AU1693995A (en) Phosphacan, nucleic acids encoding thereof and antibodies thereto
WO1998018818A3 (en) Hepatitis b inhibitors
AU7478098A (en) Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies
AU4483597A (en) Novel tumor proteins
ZA966615B (en) Novel perhydroisoindole derivatives, their preparation and the pharmaceutical compositions which contain them.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 134480

Country of ref document: IL

Ref document number: 98809023.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 93152/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV2000-867

Country of ref document: CZ

Ref document number: 2000/00654

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: PA/A/2000/002410

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2303424

Country of ref document: CA

Ref document number: 2303424

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020007002576

Country of ref document: KR

Ref document number: 3532000

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2000 510769

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998946052

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 503849

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 200000311

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1998946052

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-867

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007002576

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2000-867

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1998946052

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020007002576

Country of ref document: KR